LeHavreV1, France, Analysis, bibRecord, 001576

Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.

Identifieur interne : 001576 ( France/Analysis ); précédent : 001575; suivant : 001577

Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.

Auteurs : C. Lacroix [France] ; J L Tranvouez ; T. Phan Hoang ; H. Duwoos ; O. Lafont

Source :

Arzneimittel-Forschung [ 0004-4172 ] ; 1990.

RBID : pubmed:2340003

English descriptors

KwdEn :
- Adult, Chromatography, High Pressure Liquid, Female, Half-Life, Humans, Liver Cirrhosis (metabolism), Liver Function Tests, Male, Pyrazinamide (analogs & derivatives), Pyrazinamide (blood), Pyrazinamide (metabolism), Pyrazinamide (pharmacokinetics).
MESH :
- chemical , analogs & derivatives : Pyrazinamide.
- chemical , blood : Pyrazinamide.
- metabolism : Liver Cirrhosis, Pyrazinamide.
- chemical , pharmacokinetics : Pyrazinamide.
- Adult, Chromatography, High Pressure Liquid, Female, Half-Life, Humans, Liver Function Tests, Male.

Abstract

The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.

PubMed: 2340003

Affiliations:

Links to Exploration step

pubmed:2340003

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.</title>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
<affiliation wicri:level="1"><nlm:affiliation>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre</wicri:regionArea>
<placeName><settlement type="city">Le Havre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tranvouez, J L" sort="Tranvouez, J L" uniqKey="Tranvouez J" first="J L" last="Tranvouez">J L Tranvouez</name>
</author>
<author><name sortKey="Phan Hoang, T" sort="Phan Hoang, T" uniqKey="Phan Hoang T" first="T" last="Phan Hoang">T. Phan Hoang</name>
</author>
<author><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
</author>
<author><name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:2340003</idno>
<idno type="pmid">2340003</idno>
<idno type="wicri:Area/PubMed/Corpus">000441</idno>
<idno type="wicri:Area/PubMed/Curation">000441</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000441</idno>
<idno type="wicri:Area/Ncbi/Merge">000347</idno>
<idno type="wicri:Area/Ncbi/Curation">000347</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000347</idno>
<idno type="wicri:doubleKey">0004-4172:1990:Lacroix C:pharmacokinetics:of:pyrazinamide</idno>
<idno type="wicri:Area/Main/Merge">002594</idno>
<idno type="wicri:Area/Main/Curation">002524</idno>
<idno type="wicri:Area/Main/Exploration">002524</idno>
<idno type="wicri:Area/France/Extraction">001576</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.</title>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
<affiliation wicri:level="1"><nlm:affiliation>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité de Pharmacocinétique, Centre Hospitalier Général, Le Havre</wicri:regionArea>
<placeName><settlement type="city">Le Havre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tranvouez, J L" sort="Tranvouez, J L" uniqKey="Tranvouez J" first="J L" last="Tranvouez">J L Tranvouez</name>
</author>
<author><name sortKey="Phan Hoang, T" sort="Phan Hoang, T" uniqKey="Phan Hoang T" first="T" last="Phan Hoang">T. Phan Hoang</name>
</author>
<author><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
</author>
<author><name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
</author>
</analytic>
<series><title level="j">Arzneimittel-Forschung</title>
<idno type="ISSN">0004-4172</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Female</term>
<term>Half-Life</term>
<term>Humans</term>
<term>Liver Cirrhosis (metabolism)</term>
<term>Liver Function Tests</term>
<term>Male</term>
<term>Pyrazinamide (analogs & derivatives)</term>
<term>Pyrazinamide (blood)</term>
<term>Pyrazinamide (metabolism)</term>
<term>Pyrazinamide (pharmacokinetics)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Liver Cirrhosis</term>
<term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Female</term>
<term>Half-Life</term>
<term>Humans</term>
<term>Liver Function Tests</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pharmacokinetics of pyrazinamide (Pirilène) and its metabolites are evaluated in ten subjects with hepatic insufficiency, after an oral dose of 19.3 +/- 0.6 mg.kg-1 and the results are compared to those of a group of nine healthy subjects (control group). The results exhibit a marked reduction of the pyrazinamide total clearance (0.48 vs 0.84 ml.min-1.kg-1) and an increase in half-life from 9.19 h to 15.07 h in the patients group. The area under the curve of pyrazinoic acid (the main metabolite) is increased from 97 to 280 mg.h.l-1 with a half-life twice as much as that of the control group. The hepatic insufficiency entails a marked reduction of the common posology as well as a closer survey of the biologic hepatic parameters and of uric acid the renal elimination of which is inhibited by pyrazinoic acid.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<settlement><li>Le Havre</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
<name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
<name sortKey="Phan Hoang, T" sort="Phan Hoang, T" uniqKey="Phan Hoang T" first="T" last="Phan Hoang">T. Phan Hoang</name>
<name sortKey="Tranvouez, J L" sort="Tranvouez, J L" uniqKey="Tranvouez J" first="J L" last="Tranvouez">J L Tranvouez</name>
</noCountry>
<country name="France"><noRegion><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001576 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 001576 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/France
   |area=    LeHavreV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:2340003
   |texte=   Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i   -Sk "pubmed:2340003" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a LeHavreV1

This area was generated with Dilib version V0.6.25.
Data generation: Sat Dec 3 14:37:02 2016. Site generation: Tue Mar 5 08:25:07 2024

Serveur d'exploration sur la visibilité du Havre

Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.

Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur la visibilité du Havre
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.